ADMA stock icon

ADMA Biologics
ADMA

$12.78
3.82%
 

About: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Employees: 624

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 11 analysts
0
News positive %
of 9 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

3,163% more call options, than puts

Call options by funds: $3.04M | Put options by funds: $93K

129% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 21

62% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 53

51% more capital invested

Capital invested by funds: $765M [Q4 2023] → $1.15B (+$387M) [Q1 2024]

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 6 (+2) [Q1 2024]

15% more funds holding

Funds holding: 184 [Q4 2023] → 211 (+27) [Q1 2024]

1.56% more ownership

Funds ownership: 74.86% [Q4 2023] → 76.42% (+1.56%) [Q1 2024]

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
53%
downside
Avg. target
$10.14
21%
downside
High target
$15
17%
upside

11 analyst ratings

11 positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Kristen Kluska
17%upside
$15
Overweight
Maintained
9 Jul 2024
Mizuho
Anthony Petrone
10%upside
$14
Buy
Maintained
20 Jun 2024
Raymond James
Elliot Wilbur
22%downside
$10
Strong Buy
Maintained
10 May 2024
Cantor Fitzgerald
Kristen Kluska
22%downside
$10
Overweight
Maintained
10 May 2024
HC Wainwright & Co.
Raghuram Selvaraju
22%downside
$10
Buy
Maintained
10 May 2024

Financial journalist opinion

Based on 9 articles about ADMA published over the past 30 days